The Urgent Need for Triple-Negative Breast Cancer Breakthroughs with Dr. Elisa Port
Mar 1st, 2022 by bcrf
Triple negative breast cancer (TNBC) makes up about 15 percent of all the breast cancers diagnosed. And, better therapeutic strategies are urgently needed to treat this breast cancer subtype. BCRF Investigator, Dr. Elisa Port is working to combat drug resistance in TNBC by developing a drug for the protein PRKCQ—a promising therapeutic target that may make TNBC more responsive to chemotherapy.